Troncoso Rodrigo, Paredes Felipe, Parra Valentina, Gatica Damián, Vásquez-Trincado César, Quiroga Clara, Bravo-Sagua Roberto, López-Crisosto Camila, Rodriguez Andrea E, Oyarzún Alejandra P, Kroemer Guido, Lavandero Sergio
Advanced Center for Chronic Disease (ACCDiS); University of Chile; Santiago, Chile; Center for Molecular Studies of the Cell; Faculty of Chemical & Pharmaceutical Sciences & Faculty of Medicine; University of Chile; Santiago, Chile.
Advanced Center for Chronic Disease (ACCDiS); University of Chile; Santiago, Chile; Center for Molecular Studies of the Cell; Faculty of Chemical & Pharmaceutical Sciences & Faculty of Medicine; University of Chile; Santiago, Chile; Department of Internal Medicine (Cardiology Division); University of Texas Southwestern Medical Center; Dallas, TX USA.
Cell Cycle. 2014;13(14):2281-95. doi: 10.4161/cc.29272. Epub 2014 Jun 4.
Glucocorticoids, such as dexamethasone, enhance protein breakdown via ubiquitin-proteasome system. However, the role of autophagy in organelle and protein turnover in the glucocorticoid-dependent atrophy program remains unknown. Here, we show that dexamethasone stimulates an early activation of autophagy in L6 myotubes depending on protein kinase, AMPK, and glucocorticoid receptor activity. Dexamethasone increases expression of several autophagy genes, including ATG5, LC3, BECN1, and SQSTM1 and triggers AMPK-dependent mitochondrial fragmentation associated with increased DNM1L protein levels. This process is required for mitophagy induced by dexamethasone. Inhibition of mitochondrial fragmentation by Mdivi-1 results in disrupted dexamethasone-induced autophagy/mitophagy. Furthermore, Mdivi-1 increases the expression of genes associated with the atrophy program, suggesting that mitophagy may serve as part of the quality control process in dexamethasone-treated L6 myotubes. Collectively, these data suggest a novel role for dexamethasone-induced autophagy/mitophagy in the regulation of the muscle atrophy program.
糖皮质激素,如地塞米松,通过泛素 - 蛋白酶体系统增强蛋白质分解。然而,自噬在糖皮质激素依赖性萎缩程序中细胞器和蛋白质周转中的作用仍不清楚。在此,我们表明地塞米松刺激L6肌管中自噬的早期激活,这取决于蛋白激酶AMPK和糖皮质激素受体活性。地塞米松增加包括ATG5、LC3、BECN1和SQSTM1在内的几种自噬基因的表达,并触发与DNM1L蛋白水平升高相关的AMPK依赖性线粒体碎片化。这个过程是地塞米松诱导的线粒体自噬所必需的。用Mdivi-1抑制线粒体碎片化会导致地塞米松诱导的自噬/线粒体自噬中断。此外,Mdivi-1增加与萎缩程序相关基因的表达,表明线粒体自噬可能是地塞米松处理的L6肌管中质量控制过程的一部分。总体而言,这些数据表明地塞米松诱导的自噬/线粒体自噬在肌肉萎缩程序调节中具有新作用。